AR040177A1 - Sal de formiato de o-desmetil-venlafaxina - Google Patents

Sal de formiato de o-desmetil-venlafaxina

Info

Publication number
AR040177A1
AR040177A1 ARP030102045A ARP030102045A AR040177A1 AR 040177 A1 AR040177 A1 AR 040177A1 AR P030102045 A ARP030102045 A AR P030102045A AR P030102045 A ARP030102045 A AR P030102045A AR 040177 A1 AR040177 A1 AR 040177A1
Authority
AR
Argentina
Prior art keywords
venlafaxina
desmetil
salt
format salt
format
Prior art date
Application number
ARP030102045A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29736291&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR040177(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR040177A1 publication Critical patent/AR040177A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Abstract

Se provee una sal de O-desmetilvenlafaxina, formiato de O-desmetilvenlafaxina. También se proveen composiciones farmacéuticas, formas de dosificación y métodos de uso. Reivindicación 3: El compuesto de acuerdo con la reivindicación 1 que tiene un punto endotérmico en aproximadamente 152° C. Reivindicación 5: El compuesto de acuerdo con la reivindicación 1 que tiene un tamano de partícula inferior a aproximadamente 26 micrones.
ARP030102045A 2002-06-10 2003-06-09 Sal de formiato de o-desmetil-venlafaxina AR040177A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38732102P 2002-06-10 2002-06-10

Publications (1)

Publication Number Publication Date
AR040177A1 true AR040177A1 (es) 2005-03-16

Family

ID=29736291

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030102045A AR040177A1 (es) 2002-06-10 2003-06-09 Sal de formiato de o-desmetil-venlafaxina

Country Status (20)

Country Link
US (2) US7001920B2 (es)
EP (1) EP1519720A4 (es)
JP (1) JP4445853B2 (es)
KR (1) KR20050013125A (es)
CN (1) CN1658861A (es)
AR (1) AR040177A1 (es)
AU (1) AU2003247515A1 (es)
BR (1) BR0311693A (es)
CA (1) CA2488613A1 (es)
CR (1) CR7583A (es)
EC (1) ECSP045491A (es)
IL (1) IL165584A0 (es)
MX (1) MXPA04012347A (es)
NO (1) NO20045065L (es)
NZ (1) NZ537142A (es)
RU (1) RU2004139075A (es)
TW (1) TW200407108A (es)
UA (1) UA84271C2 (es)
WO (1) WO2003103603A2 (es)
ZA (1) ZA200409981B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7579160B2 (en) * 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
US6342533B1 (en) * 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
NZ514612A (en) * 1999-04-06 2004-01-30 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
EP2319826A1 (en) 2001-02-12 2011-05-11 Wyeth LLC Succinate salt of O-desmethyl-venlafaxin
TW200402289A (en) * 2002-05-17 2004-02-16 Wyeth Corp Methods of treating gastrointestinary and genitourinary pain disorders
PE20040134A1 (es) 2002-07-25 2004-03-06 Pharmacia Corp Forma de dosificacion de una vez al dia de pramipexol
EP1523981A1 (en) * 2003-10-13 2005-04-20 Wyeth Extended release formulations of venlafaxine
CA2554559A1 (en) * 2004-02-06 2005-08-25 Wyeth Multiparticulate o-desmethylvenlafaxine salts and uses thereof
JP4757872B2 (ja) * 2004-08-13 2011-08-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング プラミペキソール又はその医薬品として許容される塩を含む放出が延長された錠剤調合物、その製造方法及びその使用
MX2008000249A (es) * 2005-07-06 2008-03-18 Sepracor Inc Combinaciones de eszopiclona y o-desmetilvenlafaxina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y cognitivos.
GT200600396A (es) * 2005-09-07 2007-04-23 Dispositivos para la aplicacion de medicamentos transdermicos conteniendo o-desmetil venlafaxina (odv) o sus sales
GT200600397A (es) * 2005-09-07 2007-08-28 Formulas topicas conteniendo o-desmetil venlafaxina (odv) o sus sales
WO2009027766A2 (en) * 2006-12-22 2009-03-05 Medichem, S.A. New crystalline solid forms of o-desvenlafaxine base
CN101663263A (zh) * 2007-02-21 2010-03-03 塞普拉柯公司 包含(-)-o-去甲基文拉法辛的固体形式及其用途
TR200909798T1 (tr) * 2007-07-12 2010-05-21 Dr. Reddy's Laboratories Ltd. O-desmetilvenlafaksin.
US20090076162A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched desvenlafaxine
CN101938998A (zh) * 2007-10-16 2011-01-05 阿尔法制药有限公司 控释药物制剂
EP2212275A2 (en) * 2007-10-22 2010-08-04 Actavis Group PTC EHF Solid forms of (±)-o-desmethylvenlafaxine salts
AU2008315740A1 (en) * 2007-10-26 2009-04-30 Generics [Uk] Limited Process for preparing O-desmethylvenlafaxine
EP2085377A1 (en) 2008-01-29 2009-08-05 LEK Pharmaceuticals D.D. Novel salts of O-desmethyl-venlafaxine
WO2009114685A2 (en) * 2008-03-12 2009-09-17 Dr. Reddy's Laboratories Ltd. O-desmethylvenlafaxine salts
IN2008CH00818A (es) * 2008-04-01 2009-10-09 Actavis Group Ptc Ehf
EP2119696A1 (en) 2008-05-16 2009-11-18 Krka Preparation of O-desmethylvenlafaxine salts
EP2119695A1 (en) 2008-05-16 2009-11-18 Krka Preparation of O-desmethylvenlafaxine salts
WO2009155488A2 (en) * 2008-06-19 2009-12-23 Segrub, Llc Novel oxalate salt and crystal of o-desmethylvenlafaxine
KR101022335B1 (ko) * 2008-08-01 2011-03-22 제일약품주식회사 신규4-(2-(디메틸아미노)-1-(1-하이드록시사이클로헥실)에틸)페녹시 유도체 또는 이의 약학적으로 허용가능한 염, 이의제조방법 및 이를 유효성분으로 함유하는 중추신경계 질환예방 및 치료용 조성물
CN101716168B (zh) * 2008-10-09 2014-09-17 北京德众万全医药科技有限公司 一种含有去甲文拉法新的盐的药物组合物及其制备方法
EP2191822A1 (en) 2008-11-26 2010-06-02 LEK Pharmaceuticals d.d. Controlled release pharmaceutical compositions comprising O-desmethyl-venlafaxine
CZ301820B6 (cs) * 2009-02-06 2010-06-30 Zentiva, K.S. Nové soli desvenlafaxinu a zpusob jejich prípravy
BR112012024576A2 (pt) 2010-03-31 2016-05-31 Wockhardt Ltd composição farmacêutica de liberação modificada compreendendo desvenlafaxina ou sais da mesma e processo para preparação da dita composição
CN102249936B (zh) * 2010-05-19 2014-09-17 江苏豪森医药集团有限公司 O-去甲基文拉法辛盐酸盐的水合物及其制备方法
RU2453559C1 (ru) * 2010-10-11 2012-06-20 Общество С Ограниченной Ответственностью "Ниармедик Плюс" Способ получения сополимера натрийкарбоксиметилцеллюлозы и госсипола и его применение в комплексной терапии пациентов с аутистическими расстройствами и когнитивными нарушениями
KR20140030156A (ko) 2011-04-12 2014-03-11 루핀 리미티드 방출-조절되는 데스벤라팍신 약학 조성물
US8481596B2 (en) 2011-06-08 2013-07-09 Lupin Limited Polymomorph of desvenlafaxine benzoate
CN102349879B (zh) * 2011-10-14 2016-07-13 北京科信必成医药科技发展有限公司 一种去甲文拉法辛控释片及其制备方法
WO2015031410A1 (en) * 2013-08-26 2015-03-05 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
CN112010772A (zh) * 2016-01-26 2020-12-01 赵鸣 5-氨基酮戊酸及其衍生物的盐化合物和应用
TR201820634A2 (tr) 2018-12-27 2020-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Desvenlafaksi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
IE56324B1 (en) 1982-12-13 1991-06-19 American Home Prod Phenethylamine derivatives and intermediates therefor
US6562629B1 (en) * 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6342533B1 (en) * 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
US6197828B1 (en) * 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
NZ514612A (en) 1999-04-06 2004-01-30 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
IT1308475B1 (it) * 1999-05-07 2001-12-17 Gate Spa Motoventilatore, particolarmente per uno scambiatore di calore di unautoveicolo
WO2000076955A1 (en) 1999-06-15 2000-12-21 American Home Products Corporation Enantiomers of o-desmethyl venlafaxine
US6348494B1 (en) * 2000-11-21 2002-02-19 American Home Products Corporation Ethers of o-desmethyl venlafaxine
CA2419115C (en) * 2000-08-15 2011-03-08 Board Of Trustees Of The University Of Illinois Microparticles, and method and apparatus for forming same
EP2319826A1 (en) * 2001-02-12 2011-05-11 Wyeth LLC Succinate salt of O-desmethyl-venlafaxin
EP1392262A1 (en) * 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route

Also Published As

Publication number Publication date
JP2005533772A (ja) 2005-11-10
CA2488613A1 (en) 2003-12-18
EP1519720A2 (en) 2005-04-06
IL165584A0 (en) 2006-01-15
AU2003247515A1 (en) 2003-12-22
UA84271C2 (en) 2008-10-10
US7001920B2 (en) 2006-02-21
MXPA04012347A (es) 2005-02-25
WO2003103603A2 (en) 2003-12-18
US7154001B2 (en) 2006-12-26
ZA200409981B (en) 2010-05-26
KR20050013125A (ko) 2005-02-02
TW200407108A (en) 2004-05-16
CN1658861A (zh) 2005-08-24
NO20045065L (no) 2005-01-07
WO2003103603A3 (en) 2004-03-25
US20060058552A1 (en) 2006-03-16
BR0311693A (pt) 2005-03-22
US20030236309A1 (en) 2003-12-25
CR7583A (es) 2008-08-21
RU2004139075A (ru) 2005-06-27
EP1519720A4 (en) 2010-02-10
JP4445853B2 (ja) 2010-04-07
NZ537142A (en) 2008-01-31
ECSP045491A (es) 2005-03-10

Similar Documents

Publication Publication Date Title
AR040177A1 (es) Sal de formiato de o-desmetil-venlafaxina
PA8539901A1 (es) Novedosa sal de succinato de o-desmetil-venlafaxina
RS52607B (en) SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING VALSARTAN
BRPI0417684A (pt) composto, composição farmacêutica, e, uso de um composto
RS52388B (sr) Kiseli preparati insulina sa poboljšanom stabilnošću
ATE286057T1 (de) Pharmazeutische zubereitungen enthaltend clavulansäure
DE69907977D1 (de) Pyrrolobenzodiazepine
EA200600620A1 (ru) Набор для ингаляции с ингаляционным порошком, содержащим тиотропий
ES2157993T3 (es) Benzoilguanidinas, su preparacion y su uso en medicamentos.
EA200401446A1 (ru) Иммуноконъюгаты для лечения опухолей
CL2007001752A1 (es) Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral.
BR0314058A (pt) Composições para cuidados pessoais a base de álcool ramificado
AR029509A1 (es) Una composicion farmaceutica en base a un compuesto de platino (iv) y el uso de dicho compuesto para preparar medicamentos antitumorales
RU2007115030A (ru) Ультразвуковой распылитель жидких препаратов различной вязкости
UY27727A1 (es) Nueva composicion farmacéutica-
EA200400819A1 (ru) Парентеральная композиция парацетамола
WO2006109175A3 (en) Solid dosage form of an antidiabetic drug
ES2231176T3 (es) Uso de beta-(1,3)-glucanos nanometricos hidrosolubles.
EA200501391A1 (ru) Способ получения кристаллического циклесонида, обладающего определенным размером частиц
CL2021002252A1 (es) Composición farmacéutica que comprende paracetamol e ibuprofeno
IS6654A (is) Stöðugt gabapentín með pH innan stýrðra marka
EA200100540A1 (ru) Фармацевтическая композиция с модифицированным высвобождением сенсибилизатора к инсулину
ES2422081T3 (es) Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales
EA200501046A1 (ru) Эсциталопрамгидробромид и способ его получения
BR0114814A (pt) Composições compreendendo composto de modafinila e seu uso

Legal Events

Date Code Title Description
FB Suspension of granting procedure